References
- Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. (2009). Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol 142:99–105.
- Bottoni P, Scatena R. (2015). The role of CA 125 as tumor marker: biochemical and clinical aspects introduction: biochemical. Adv Exp Med Biol 867:229–44.
- John G, Rustin S, Vergote I, et al. (2011). Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1. 1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21:419–23.
- Duffy MJ, van Dalen A, Haglund C, et al. (2007). Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43:1348–60.
- Goonetilleke KS, Siriwardena AK. (2007 Apr). Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33:266–70.
- Saijo N. (2012 Feb). Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. Cancer Treat Rev 38:63–7.
- Ross A, Sardi A, Nieroda C, et al. (2010 Aug). Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC. Eur J Surg Oncol 36:772–6.
- Makar A, Kristensen G, Kaern J, et al. (1992). Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obs Gynecol 79:1002–10.
- Gupta D, Lis CG. (2009). Role of CA125 in predicting ovarian cancer survival – a review of the epidemiological literature. J Ovarian Res 2:13.
- Talbot R, Jacobsen D, Nagorney D, et al. (1989). Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obs 168:407–12.
- Atmaca R, Balat O, Cekmen M, et al. (2004). Changes in serum CA-125 levels after laparotomy. Eur J Gynaecol Oncol 25:733–4.
- van der Zee A, Duk J, Aalders J, et al. (1990). The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. Br J Obstet GynaecolGynaecol 97:934–8.
- Chee M, Ong W, Teo M. (2016). Tumour markers in CRS-HIPEC patients: an analysis of 157 patients in a single institution. Ann Surg Oncol 20:407.
- R Development Core Team. (2008). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. ISBN 3-900051-07-0. URL http://www.R-project.org
- Yedema CA, Kenemans P, Thomas CM, et al. (1993). CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery. Eur J Cancer 29:966–71.
- Mogensen O, Brock A, Holm Nyland M. (1993). CA 125 measurements in ovarian cancer patients during their first postoperative week. Int J Gynecol Cancer 3:54–6.
- Epiney M, Bertossa C, Weil A, et al. (2000). CA125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 15:1261–5.